Investigation of The Effects of FOLFOX and CAPOX Chemotherapy Protocols on CEA and CA 19-9 in Colon Cancer

Birsen Ecem İbabay; Elif Ercan; Ahmet Çarhan

Makale detayları

Investigation of The Effects of FOLFOX and CAPOX Chemotherapy Protocols on CEA and CA 19-9 in Colon Cancer

Yazarlar:

Birsen Ecem İbabay | Elif Ercan | Ahmet Çarhan

Yayıncı:

Gumushane University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi Vol.12 Issue 4, pp.2015-2020

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001306973

pISSN:

2146-9954

Anahtar kelimeler:

Özet:

 The most common markers used in the diagnosis of the colon cancer are CEA and CA 19-9. Chemotherapy is applied as an adjuvant and a neo-adjuvant treatment in colon cancer. Our aim was to investigate the effects of FOLFOX and CAPOX on CEA and CA 19-9 levels before and after chemotherapy in different patient groups. The CEA and CA 19-9 values before and after chemotherapy for the 60 patients diagnosed with metastatic colon cancer having FOLFOX or CAPOX therapy age over 18 whom hospitalised between 2017-2020, were used. The mean value for CA 19-9 of T0 for FOLFOX receiving group was calculated as 263.71  709.87 Uml and was 119.57  246.34 Uml of for the 3rd month. The mean value for CEA for receiving FOLFOX was calculated as 76.11  204.22 ngg at T0, and 50.53  142.50 ngg at the 3rd month. The mean value of CEA for receiving CAPOX was calculated as 139.62  388.87 ngg at T0, and 117.05  272.08 ngg at the 3rd month. Intertemporal CEA levels of individuals receiving CAPOX were found to show significant differences p0.074. CA 19-9 mean of T0 was calculated as 218.43  605.53 Uml and the 3rd month mean of 174.40  465.61 Uml of the patients receiving CAPOX. It was found that the intertemporal values of the individuals in terms of CA 19-9 levels were not statistically significant p0.649. In conclusion, CA 19-9 and CEA levels of the patients decreased even more in the 3rd month when treated with FOLFOX. The decrease in CEA was found to be more significant. In terms of CAPOX treatment, the interquartile range T0 and the 3rd month levels did not show a significant difference, statistically p0.143 and p0.089.

 The most common markers used in the diagnosis of the colon cancer are CEA and CA 19-9. Chemotherapy is applied as an adjuvant and a neo-adjuvant treatment in colon cancer. Our aim was to investigate the effects of FOLFOX and CAPOX on CEA and CA 19-9 levels before and after chemotherapy in different patient groups. The CEA and CA 19-9 values before and after chemotherapy for the 60 patients diagnosed with metastatic colon cancer having FOLFOX or CAPOX therapy age over 18 whom hospitalised between 2017-2020, were used. The mean value for CA 19-9 of T0 for FOLFOX receiving group was calculated as 263.71  709.87 Uml and was 119.57  246.34 Uml of for the 3rd month. The mean value for CEA for receiving FOLFOX was calculated as 76.11  204.22 ngg at T0, and 50.53  142.50 ngg at the 3rd month. The mean value of CEA for receiving CAPOX was calculated as 139.62  388.87 ngg at T0, and 117.05  272.08 ngg at the 3rd month. Intertemporal CEA levels of individuals receiving CAPOX were found to show significant differences p0.074. CA 19-9 mean of T0 was calculated as 218.43  605.53 Uml and the 3rd month mean of 174.40  465.61 Uml of the patients receiving CAPOX. It was found that the intertemporal values of the individuals in terms of CA 19-9 levels were not statistically significant p0.649. In conclusion, CA 19-9 and CEA levels of the patients decreased even more in the 3rd month when treated with FOLFOX. The decrease in CEA was found to be more significant. In terms of CAPOX treatment, the interquartile range T0 and the 3rd month levels did not show a significant difference, statistically p0.143 and p0.089.

 The most common markers used in the diagnosis of the colon cancer are CEA and CA 19-9. Chemotherapy is applied as an adjuvant and a neo-adjuvant treatment in colon cancer. Our aim was to investigate the effects of FOLFOX and CAPOX on CEA and CA 19-9 levels before and after chemotherapy in different patient groups. The CEA and CA 19-9 values before and after chemotherapy for the 60 patients diagnosed with metastatic colon cancer having FOLFOX or CAPOX therapy age over 18 whom hospitalised between 2017-2020, were used. The mean value for CA 19-9 of T0 for FOLFOX receiving group was calculated as 263.71  709.87 Uml and was 119.57  246.34 Uml of for the 3rd month. The mean value for CEA for receiving FOLFOX was calculated as 76.11  204.22 ngg at T0, and 50.53  142.50 ngg at the 3rd month. The mean value of CEA for receiving CAPOX was calculated as 139.62  388.87 ngg at T0, and 117.05  272.08 ngg at the 3rd month. Intertemporal CEA levels of individuals receiving CAPOX were found to show significant differences p0.074. CA 19-9 mean of T0 was calculated as 218.43  605.53 Uml and the 3rd month mean of 174.40  465.61 Uml of the patients receiving CAPOX. It was found that the intertemporal values of the individuals in terms of CA 19-9 levels were not statistically significant p0.649. In conclusion, CA 19-9 and CEA levels of the patients decreased even more in the 3rd month when treated with FOLFOX. The decrease in CEA was found to be more significant. In terms of CAPOX treatment, the interquartile range T0 and the 3rd month levels did not show a significant difference, statistically p0.143 and p0.089.

 Kolon kanseri tanısında en sık kullanılan belirteçler CEA ve CA 19-9dur. Kolon kanserinde Kemoterapi uygulaması adjuvan ve neo-adjuvan olarak yapılmaktadır. Çalışmadaki amacımız, FOLFOX ve CAPOX un farklı hasta gruplarında kemoterapi öncesi ve sonrası CEA ve CA 19-9 düzeylerine etkilerini araştırmaktı. 2017-2020 yılları arasındaki, 18 yaş üstü FOLFOX veya CAPOX kemoterapi protokolü alan, metastatik kolon kanseri tanısı almış 60 hastanın kemoterapi öncesi T0 ve 3. aydaki CEA ve CA 19-9 değerleri kullanılmıştır. FOLFOX tedavisi alan hastaların ortalama CA 19-9 değerleri T0da 263,71  709,87 UmL ve 3.ayda 119,57  246,34 UmL, CEA değerleri T0da 76,11  204,22 nggr ve 3.ayda 50,53  142,50 nggr olarak hesaplanmıştır. CAPOX alan grupta ortalama CEA değeri T0da 139,62  388,87 nggr ve 3.ayda 117,05  272,08 nggr olarak hesaplanmıştır. CAPOX alan bireylerde başlangıç ve 3.ayda CEA düzeylerindeki farklılıklar anlamlı bulunmuştur p0,074. CAPOX alan hastaların CA 19-9 ortalaması T0da 218,43  605,53 UmL ve 3.ayda 174,40  465,61 UmL olarak hesaplanmıştır. Bireylerin başlangıç ve 3.ay CA 19-9 değerleri istatistiksel olarak anlamlı bulunmamıştır p0,649. Sonuç olarak, FOLFOX ile tedavi edilen hastaların CA 19-9 ve CEA seviyelerinin 3. ayda daha da düştüğü bulunmuş ve CEA seviyelerindeki azalma daha anlamlı bulunmuştur. CAPOX tedavisi alanlarda, çeyrekler arası başlangıç ve 3. ay seviyeleri istatistiksel olarak anlamlı bulunmamıştır p0,143 ve p0,089.

Makale detayları

Investigation of The Effects of FOLFOX and CAPOX Chemotherapy Protocols on CEA and CA 19-9 in Colon Cancer

Yazarlar:

Birsen Ecem İbabay | Elif Ercan | Ahmet Çarhan

Yayıncı:

Gumushane University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi Vol.12 Issue 4, pp.2015-2020

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001306973

pISSN:

2146-9954

CA 19-9

CAPOX

CEA

Colon Cancer

FOLFOXCA 19-9

CAPOX

CEA

FOLFOX

Kolon Kanseri

Sayı

Makale detayları

Yazarlar: Birsen Ecem İbabay | Elif Ercan | Ahmet Çarhan

Yayıncı: Gumushane University

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi Vol.12 Issue 4, pp.2015-2020

Belge Tipi: Makale

Yayın Tarihi: 12/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001306973

pISSN: 2146-9954

Sayı

Yazarlar:

Birsen Ecem İbabay | Elif Ercan | Ahmet Çarhan

Yayıncı:

Gumushane University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi Vol.12 Issue 4, pp.2015-2020

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001306973

pISSN:

2146-9954